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The vascular complications of diabetes significantly impact the quality of life and mortality in diabetic patients. Extensive evidence
from various human clinical trials has clearly established that a period of poor glycemic control early in the disease process
carries negative consequences, such as an increase in the development and progression of vascular complications that becomes
evident many years later. Importantly, intensive glycemic control established later in the disease process cannot reverse or slow
down the onset or progression of diabetic vasculopathy. This has been named the glycemic memory phenomenon. Scientists have
successfully modelled glycemic memory using various in vitro and in vivo systems. This review emphasizes that oxidative stress
and accumulation of advanced glycation end products are key factors driving glycemic memory in endothelial cells. Furthermore,
various epigenetic marks have been proposed to closely associate with vascular glycemic memory. In addition, we comment on
the importance of endothelial progenitors and their role as endogenous vasoreparative cells that are negatively impacted by the
diabetic milieu and may constitute a “carrier” of glycemic memory. Considering the potential of endothelial progenitor-based
cytotherapies, future studies on their glycemic memory are warranted to develop epigenetics-based therapeutics targeting diabetic
vascular complications.
1. Introduction
The concept of glycemic memory refers to the inexorable
progression of diabetic vascular complications which is
linked to uncontrolled glycemia early in the disease despite a
significant follow-on period of improved glycemic control. It
also relates to the association between tight glycemic control
early in the course of disease and prevention of progression
to late macrovascular, retinopathic, and neuropathic compli-
cations, independently of future glycemic control strategies.
The glycemic memory phenomenon was initially found by
Engerman and Kern in diabetic dogs in 1987 [1]. This
investigation was designed following preliminary clinical
studies reporting that diabetic retinopathy progression could
not be arrested but worsened with tighter glycemic control
[2, 3] and established that diabetic retinopathy could be
prevented in diabetic dogs only if tight glycemic control
began within 2 months of diabetes onset. Tight glycemic
control starting 2.5 years after diabetes onset did not halt dia-
betic retinopathy progression, and interestingly retinopathy
became evident during the tight glycemic period [1]. This
preclinical study was clinically validated with results from
the Diabetes Control and Complications Trial (DCCT) [4]
and its follow-up the Epidemiology of Diabetes Interventions
andComplications (EDIC) trial [5].TheDCCT/EDIChuman
clinical trials have demonstrated that the level of glycemic
control early in the disease process will dictate the speed of
progression for diabetic retinopathy [6].
Glycemic memory is often described using diverse
nomenclature such as metabolic memory [7, 8], delayed toxi-
city of prior chronic hyperglycemia [9], metabolic imprint-
ing [10], latent hyperglycemic damage [11], hyperglycemic
legacy effect [12], and posthyperglycemic normoglycemic
damage [9] (Figure 1). Metabolic memory is the broader
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Figure 1:Word cloud illustrating diverse nomenclature for glycemic
memory and associated diabetic complications.
term which refers to the delayed adverse effects triggered
by prior exposure to glucotoxicity, lipotoxicity, and other
metabolic imbalances. Because hyperglycemia is considered
a key mechanistic driver for diabetic vascular complications
and most in vitro experimental models have been based
solely on high glucose exposure, here we endorse the term
glycemic memory. However, metabolic memory is often used
as an interchangeable term to describe this phenomenon,
because it has been proposed thatmore than just tight glucose
control is needed to prevent diabetic complications [13]. This
review summarizes past and recent research on the role of
glycemic memory in the prognosis of diabetic micro and
macro vascular complications, covering fromexperimental in
vitromodels to human clinical trials. In addition, it discusses
the relevance of epigenetics, with particular focus on how this
might impact on endothelial progenitors as one of the cellular
substrates of glycemic memory.
2. Diabetic Vascular Complications and
the Glycemic Memory Phenomenon
Diabetes is an epidemic of increasing global concern as it
causes serious health outcomes leading to reduced quality of
life and a decreased life expectancy. Currently 382 million
people (8.2% of adults) have been diagnosed with diabetes
and 5.1 million diabetes-related deaths have been reported in
2013 [14].Theworldwide prevalence of diabetes has been esti-
mated to increase up to 55% by 2035 [15]. Furthermore, due to
the constant increase in the aging population, improvements
in the health care system, and increased life expectancy for
diabetic patients, we are likely to witness a rapid increase in
the incidence of complications such as micro- andmacrovas-
culopathy. The key cause of mortality and morbidity due to
diabetes has been attributed to its impact on organs leading to
outcomes such as blindness, renal failure, limb amputations,
stroke, and myocardial infarction. At the heart of these vas-
cular complications is a so-called “endotheliopathy” which
is a progressive endothelial dysfunction leading to micro-
andmacrovascular damage [16]. Data indicating that vascular
injury is responsible for diabetic retinopathy, nephropathy,
and neuropathy underscore the endothelium as a cellular
target susceptible to injury during diabetes.
Hyperglycemia is a clinical hallmark of both type 1
and type 2 diabetes which can be regulated by drugs that
increase insulin secretion, suppress glucose release from the
liver, delay glucose absorption, or increase the utilization of
glucose by fat and skeletal muscle [17]. In spite of improved
glucose monitoring technologies and advances in effective
hyperglycemia control measures, the development of one or
more vascular complications is a prospect for most diabetic
patients [18, 19]. Macrovascular complications result in an
increased risk of cardiovascular diseases like myocardial
infarction and stroke. It has been reported that patients with
type 1 and type 2 diabetes possess a two- to fourfold higher
risk of vascular complications when compared to healthy
individuals [20].
Glycemic memory is a concept that has gained impor-
tance and clinical relevance due to a persistent rise in diabetic
complications. Here we describe some of the pioneer studies
and recent research that provides evidence for the existence
of this phenomenon in endothelial cells.
2.1. In Vitro Cellular Models. To study the poor reversibility
of diabetic vascular complications, an in vitro model was
designed 25 years ago using human endothelial cells that
were cultured under 5mM or 50mM glucose for up to 3
weeks [21]. High glucose treatment induced a significant
increase in the gene expression of fibronectin and collagen
IV. The finding that this overexpression of extracellular
matrix genes persisted even after cells were switched back to
normal glucose levels constituted key evidence to establish
the glycemicmemory phenomenon at the endothelial cellular
level [21].
A seminal dissection of the glycemic memory phe-
nomenon came from the Brownlee lab. Transient exposure
of aortic endothelial cells to high glucose levels of 30mM for
16 hours led to long-lasting activation of the NF𝜅B p65 gene.
This increase in gene expression persisted for up to 6 days
after return to normal glucose levels [22]. In addition, the
upregulatedNF𝜅Bp65 transcript also induced persistent high
expression of inflammatory proteins MCP-1 and VCAM1
even when high glucose was not present [22].
Another model to study glycemic memory used human
aortic endothelial cells and exposed them for 6 days to 5mM
or 25mM of glucose as control and high glucose groups,
respectively. The memory group consisted of cells treated
with high glucose for the first 3 days and then normal glucose
for the last 3 days. Assessment of superoxide production
and peroxynitrite levels indicated that both remained signifi-
cantly elevated in the high glucose andmemory groups, when
compared to the control group [23]. This increase in reactive
oxygen species (ROS) correlated with the overexpression
of p66 (Shc) which was suggested as a key driver for
hyperglycemic memory in the vasculature [23].
Long-duration in vitro models have also been used.
Human umbilical vein endothelial cells (HUVECs) were
cultured for 21 days under normal glucose (5mM) or high
glucose (30mM) [24]. Treatment for thememory experimen-
tal group in this case consisted of high glucose for 14 days
followed by 7 days under normal glucose. The high glucose-
treated cells showed significant increases in ROS, 8OHdG,
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and caspase-3. These same effects were also found in the
memory group confirming that there are gene expression and
functional changes at the cellular level that persist even after
return to normal glucose conditions [24]. Another investi-
gation with similar experimental design (long-term 3-week
treatments) exposed retinal capillary endothelial cells to high
glucose for one week and then switched them back to normal
glucose for the remaining 2 weeks as their memory group.
This study reported persistent increased protein expression
of NF𝜅B, Bax, and PAR in the memory group that was
comparable to cells treated continuously under high glucose
[25]. A one-week culture under high glucose conditions
was sufficient to imprint a cellular glycemic memory in
retinal endothelial cells that remained unchanged for the
next two weeks. Sirtuin 1 was suggested as a main modulator
establishing the memory in this model [25].
It is important to highlight that most published in vitro
models have used endothelial cells derived from a variety of
vascular beds and that the initial high glucose exposures for
the memory groups ranged from 16 hours to 14 days. Despite
these differences in experimental in vitro models, similar
findings have demonstrated that some endothelial gene
expression changes cannot be immediately reversed even
after normal glucose levels were reinstituted and constitute
supportive evidence for the glycemic memory phenomenon.
It is also relevant to underscore that these in vitro studies have
identified some common findings in the memory group such
as overexpression of NF𝜅B and increased ROS production,
which suggests that oxidative stress acts as a key molecular
driver for glycemic memory.
2.2. Preclinical Animal Models. The idea that tissues and cells
retain memory of a previous glucose environment was firstly
proposed from a study on diabetic retinopathy in dogs over
25 years ago [1]. This study lasted 5 years in total and studied
4 experimental groups: nondiabetic animals, poor control
diabetics, good control diabetics, and diabetic dogs that
were switched from poor to good glycemic treatment. This
investigation showed that diabetic dogs that were switched
to good glycemic control after 2.5 years of poor glycemic
control continued to develop retinopathy in a similar way to
the poor glycemic control group [1]. This provided the first
experimental evidence demonstrating that diabetic retinopa-
thy progression persisted, despite later efforts in keeping a
good glycemic control.
Similarly, the sucrose-fed diabetic Cohen rat model has
been used to elucidate the glycemic memory phenomenon
in relation to diabetic retinopathy. Offspring that developed
abnormal glucose tolerance, glucosuria, and diabetic compli-
cations were included in the study. Diabetic rats were treated
with islet transplantation after 6 or 12 weeks of overt diabetes.
The untreated diabetic group of rats exhibited retinal pathol-
ogy characterised by increased capillary endothelial prolifer-
ation, pericyte dropout, occluded capillaries, and occasional
microaneurysms. Islet transplantation after 6 weeks in the
diabetic rats led to a significant reduction in pericyte loss
and prevented endothelial proliferation. However, transplan-
tation of islets after 12 weeks failed to prevent or reduce
retinal vessel occlusion [26]. These findings suggested that
glycemic memory is established very early in the diabetic
disease process and that lack of an early intervention worsens
diabetic retinopathy progression.
The streptozotocin-induced diabetic rat model was also
used to investigate glycemicmemory. After the establishment
of diabetes, diabetic rats are followed up to 12 months.
Animals were divided into three experimental groups: good
glycemic control (GC), poor glycemic control (PC), and the
memory group with 6 months of poor control followed by
6 months of good glycemic control (PC-GC). The number of
acellular capillarieswas significantly higher in the PCandPC-
GC than in the GC [27]. These results, quantifying acellular
capillaries, are in agreement with the findings from a study
of retinal endothelial cell apoptosis showing that six months
of good glycemic control in the diabetic rat model did not
decrease the number of TUNEL-positive cells in the PC-
GC group when compared to the PC [28]. This indicated
that retinal capillary cell apoptosis continues to develop in
diabetic rats even after 6 months of good glycemic control.
Further studies in this diabetic rat model have described that
the oxidative and nitrative retinal modifications occur early
in the diabetic retina and that these changes are not easily
reversed even after 6 months of good glycemic control [29].
An epigenetic link between glycemicmemory and persis-
tent proinflammatory phenotype in diabetic vascular smooth
muscle cells (VSMCs) has been reported in type 2 diabetic
db/db mice. This atherogenic and inflammatory phenotype
persisted in these diabetic VSMCs even after 8-week in vitro
culture under normoglycemic conditions [30]. A repres-
sive chromatin histone methylation mark, H3K9me3, was
observed to decrease at the promoters of key inflammatory
genes in diabetic VSMCs when compared to control group.
This was in agreement with a lower protein expression of
H3K9me3 methyltransferase, Suv39h1. This study highlights
the role of chromatin histone modifications associated with
the glycemic memory phenomenon.
2.3. Human Clinical Trials Comparing Conventional versus
Intensive Glycemic Control Therapies
2.3.1. Type 1 Diabetes (T1D). Among the first human clinical
trials to compare an “intensified conventional” treatment
with regular treatment for glycemic control in relation with
the development of diabetic vascular complications was
the Stockholm Diabetes Intervention Study (SDIS). SDIS
enrolled 96 patients with T1D and nonproliferative retinopa-
thy who were randomized to receive regular or intensive
glycemic control [31]. Clinical data, evaluated after 5-year
follow-up, indicated that intensive treatment significantly
delayed the development of microvascular complications of
diabetes including retinopathy, nephropathy, and neuropa-
thy, when compared to the regular treatment.
Results from the SDIS were further supported by the
seminal Diabetes Control and Complications Trial (DCCT).
This is the largest andmost frequently cited clinical trial com-
paring conventional versus intensive glycemic control in T1D.
TheDCCTwas designed as amulticentre randomized clinical
trial and enrolled 1441 T1D patients that were given con-
ventional or intensive therapy with a mean follow-up period
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of 6.5 years [4]. Both primary prevention and secondary
intervention were final read-outs. Glycosylated hemoglobin
percentageswere clearly different in theDCCTpatient groups
with median values of 9% and 7% for the conventional and
intensive treatment, respectively. Findings indicated that the
intensive therapy group benefited from a significant delay in
the onset and progression of retinopathy, nephropathy, and
neuropathy. While mortality did not differ between the treat-
ment groups, severe hypoglycemia incidents were three times
more frequently reported in the intensive therapy group. Due
to clear and consistent results at the end of the DCCT, it
was decided that all patients would be offered the intensive
therapy. A new follow-up study called the Epidemiology
of Diabetes Interventions and Complications (EDIC) was
designed.The EDIC trial recruited 1375 participants from the
DCCT. A report on 8-year follow-up indicated that previous
intensive treatment group still benefited from a delayed
progression of diabetic nephropathy [5]. 18-year follow-up
on EDIC once more demonstrated a persistent benefit for
the original intensive therapy group when compared to the
conventional one on retinopathy progression [32]. However,
reported risk reductions over 18 years were smaller than the
ones reported in earlier follow-ups. The most recent report
on DCCT/EDIC at 30 years showed a durable effect of initial
assigned therapies despite a loss of the glycemic separation
[6]. This represents consistent reliable data recognizing the
important and persistent role that glycemic memory plays in
the development and progression of vascular complications
in T1D patients.
Considering the multiple clinical reports on glycemic
memory, in order to define optimal clinical guidelines for
glycemic control in T1D patients, a systematic review was
performed to compare intensive glucose control versus con-
ventional glucose control. This report included 12 clinical
trials and a total of 2230 patients [33]. The main conclusion
was that tight glycemic control significantly reduces the
risk of developing retinopathy, nephropathy, and neuropathy.
Therefore, tight blood sugar control is recommended in
young T1D patients as early as possible after diagnosis in
order to reduce the risk of developing microvascular com-
plications. However, benefits appear to become less evident
if complications are already present, and there is lack of
evidence to demonstrate a beneficial effect of tight glycemic
control in older patients.
2.3.2. Type 2 Diabetes (T2D). Human clinical trials assessing
T2D patients by interventional studies to compare conven-
tional versus intensive glycemic control have led to conflict-
ing results and controversy. Here we discuss some of the
major outcomes of these trials.
The Kumamoto prospective clinical trial enrolled 110
Japanese patients that were randomized to receive conven-
tional or intensive treatment [34]. Clinical evaluations took
place every 6months for 6 years. Concluding data highlighted
that the intensive glycemic control delayed the onset and
progression of diabetic retinopathy, nephropathy, and neu-
ropathy. These results were supported by the Danish Steno-2
study that recruited 160 T2D patients withmicroalbuminuria
for an interventional trial to compare conventional and
intensive treatments. Mean follow-up was 7.8 years, and a
significant decline in glycosylated hemoglobin was recorded
in the intensive group. This study concluded that patients
receiving intensive treatment had a significantly lower risk of
cardiovascular disease, nephropathy, retinopathy, and auto-
nomic neuropathy [35].
Similar results were reported in the UK Prospective
Diabetes Study (UKPDS 33). UKPDS studied 3867 patients
who were randomized to receive intensive treatment with a
sulphonylurea or a conventional treatment with diet. Follow-
up over 10 years indicated that the group with intensive
treatment benefited from a significant decrease in the risk
of microvascular complications. Interestingly no differences
were reported for macrovascular disease [36]. A further
UKPDS posttrial monitoring on 3277 patients was carried
out for 5–10 years with no randomized treatment groups.
Glycated hemoglobin level differences amongUKPDS groups
were lost within one year of the posttrial. Although glycemic
levels were comparable, data indicated that there was a persis-
tent reduction inmicrovascular complications in the UKPDS
original group that received the intensive treatment 10 years
earlier. Furthermore, although the UKPDS did not find
any difference in terms of macrovascular complications, the
posttrial identified an emergent risk reduction formyocardial
infarction during the follow-up [37]. These results showed
that clinical benefits remained for up to 10 years after the
end of randomized interventions. This represents proof-of-
concept for the “legacy effect” as authors named the glycemic
memory phenomenon.
The controversy was raised by the Veterans Affairs Dia-
betes Trial (VADT) that reported no differences between
standard and intensive glucose controls in terms of develop-
ment ofmicrovascular complications ormajor cardiovascular
events. VADT studied 1791 military veterans with poorly
controlled T2D for a median follow-up of 5.6 years [38].
A substudy using 858 patients from the VADT focused
on retinopathy progression and found that a poor glucose
control at baseline was associated with increased risk of
progression of retinopathy [39]. These data suggest that
glycemicmemorymight have played a role early in the disease
pathogenesis and that the interventional VADT studywas not
able to significantly reverse it.
More conflicting results appeared with the Action in
Diabetes and Vascular Disease: Preterax and Diamicron
Modified Release Controlled Evaluation (ADVANCE) trial
which enrolled 11,140 patients for five-year follow-up compar-
ing intensive and standard glucose control [40]. ADVANCE
concluded that while there was a reduction in nephropathy
incidence in the intensive treatment group, there were no
significant differences on retinopathy ormajor cardiovascular
events.
The Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial revealed very compelling results that lead to
its early closure. 10,251 patients were randomized to receive
intensive or standard therapy. After 3.5 years, clinical data
indicated that the group receiving intensive therapy had a
significant increase in mortality and no reduction of major
cardiovascular events [41].This study highlighted, for the first
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time, the potential harm of the intensive glucose treatment in
type 2 diabetic patients.
The trials UKPDS, VADT, ADVANCE, and ACCORD
showed important but conflicting results. Some of the dif-
ferences among them might be explained by the design of
the trials [42], history and severity of diabetes, presence of
complications, glycemic control history prior to the trials,
and target patient population. For example, a recent post hoc
analysis of the VADT trial divided its patient population into
major ethnic groups. This demonstrated that while intensive
glycemic control reduced the risk for cardiovascular events in
Hispanics, this was not the case for non-HispanicWhites and
non-Hispanic Blacks [43].
In order to gain consensus for clinical guidelines, the
Global Task Force (GTF) on glycemic control has reviewed
and discussed these clinical trials. The key recommendation
is that the intensive blood glucose control may benefit certain
patient populations with moderate diabetes duration and/or
no preexisting cardiovascular disease [44]. This is in agree-
ment with the idea that the glycemicmemory phenomenon is
established early in the disease development. A long-standing
poorly controlled diabetic patient with many vascular com-
plications is likely to have a stronger predisposition for future
disease progression which becomes harder to reverse and
treat.
Although the debate on the importance of glycemic
control and the development and progression of micro-
and macrovascular complications within diabetes types and
phenotypic subgroupsmight remain unsettled [45], the broad
conclusion from such clinical trials and their follow-up
studies (Table 1) serve as compelling evidence that glycemic
memory is a robust clinical phenomenon that impacts on the
vasculopathic risk in diabetic patients.
3. Molecular Keepers of Glycemic Memory in
Endothelial Cells
3.1. Mechanisms for Diabetic Angiopathy. The vascular com-
plications that develop in diabetic patients result from a
biochemical-based injury and an impairment of protective
factors [17]. The mechanisms by which hyperglycemia dam-
ages vascular cells have been studied for many years, and
it is now accepted that pathogenesis is anchored in four
basic mechanisms: PKC activation, increased formation of
advanced glycation endproducts (AGEs), increased glucose
flux through the polyol pathway, and increased hexosamine
pathway activity [46, 47]. Moreover, the impairment of
protective factors in diabetes such as resistance to insulin,
decrease of endogenous antioxidant enzymes, and dysfunc-
tion of endothelial progenitors is as important as the injury
mechanisms [17] andmight provide novel therapeutic oppor-
tunities. Here, we focus our discussion on oxidative stress and
AGE formation because these two molecular mechanisms
(Figure 2) have been frequently associated with the glycemic
memory phenomenon.
3.2. Oxidative Stress. Hyperglycemia leads to increased glu-
cose levels within cells, tissues and in the extracellular space.
Specifically in the endothelium, there is increased transport
of glucose into the cytoplasm and an enhanced glycolytic
metabolism. This escalates formation of oxygen free radicals
derived from the mitochondria which can occur simulta-
neously with depressed activity of endogenous antioxidants
which, together, contribute to increased oxidative stress [46,
48].
Free radical production is the starting point for a cascade
of events that eventually lead to diabetic complications. Oxy-
gen free radicals produced in the mitochondria of vascular
cells trigger the activation of protein kinase C (PKC), increase
of polyol and hexamine pathway fluxes, and production of
AGEs [49, 50]. In fact, increased production of ROS, in
particular superoxide, has been proposed as the unifying
mechanism for diabetic complications [46, 47]. Hence, the
complex interconnected pathway crosstalk that starts with
free radical production has been named the “vicious cycle of
metabolic memory” [13].
ROS can also derive powerful oxidants such as peroxyni-
trite and hydrogen peroxide, which oxidise various lipids and
proteins [51], and can induce mitochondrial and DNA dam-
age [52]. Although superoxide anions are unstable species
with half-life of only a few minutes, the products resulting
from their reactions with molecules like proteins, lipids, and
nucleic acids persist for prolonged periods of time, thus
affecting cellular functions almost permanently [13].This was
demonstrated in a diabetic rat model, where reinstitution of
normoglycemia for 7months after 2months of hyperglycemic
stress reduced the levels of retinal oxidised lipids, but not
3-nitrotyrosine (3-NT), which is a protein adduct of ROS.
Interestingly, 7 months of normoglycemia after 6 months of
hyperglycemia did not result in any significant reduction in
retinal oxidative stress or 3-NT [29].
Hyperglycemia-induced oxidative stress in endothelial
cells has been reported to upregulate plasminogen activator
inhibitor 1 (PAI1) preventing fibrinolysis [53], downregulate
the platelet inhibitor prostacyclin [54], and increase produc-
tion of extracellular matrix [55]. These events collectively
increase the adhesion of macrophages and platelets to the
endothelium. Infiltration of macrophages into the endothe-
lium increases oxygen free radical formation inmitochondria
causing an additional increase of oxidative stress.
It has been demonstrated that ROS mediates the per-
sistence of vascular stress after glucose normalization in an
in vitro model using endothelial cells. Cells were exposed
for 2 weeks to continuous high glucose and returned to
normal glucose conditions for the last week. Induction of
high glucose stress markers such as PKC, NADPH oxidase,
Bax, 3-nitrotyrosine, and fibronectin persisted in endothelial
cells even after 7 days of returning to normal glucose levels.
Reduction of ROS at the mitochondrial level was an efficient
approach to erase this metabolic memory [48].
3.3. Advanced Glycation Endproducts (AGEs). AGEs result
from the nonenzymatic irreversible reaction between reduc-
ing sugars and amines of proteins, nucleic acids, and lipids.
Methylglyoxal (MGO), a dicarbonyl by-product of glycolysis,
increases extensively in diabetes. MGO is highly reactive
towards proteins and forms AGEs [56]. When MGO targets
mitochondrial proteins, it causes mitochondrial dysfunction
6 Journal of Diabetes Research
Ta
bl
e
1:
Su
m
m
ar
y
of
cli
ni
ca
lt
ria
ls
co
m
pa
rin
g
th
e
eff
ec
to
fi
nt
en
siv
e
an
d
co
nv
en
tio
na
lg
ly
ce
m
ic
co
nt
ro
lo
n
th
e
pr
og
no
sis
of
di
ab
et
ic
co
m
pl
ic
at
io
ns
in
ty
pe
1a
nd
ty
pe
2
di
ab
et
ic
pa
tie
nt
s.
∗
Re
lat
ed
to
m
ic
ro
al
bu
m
in
ur
ia
an
d
pr
ot
ei
nu
ria
le
ve
ls.
Cl
in
ic
al
tr
ia
l
Ty
pe
of
di
ab
et
es
N
um
be
ro
fc
as
es
D
ur
at
io
n
of
fo
llo
w
-u
p
(y
ea
rs
)
Eff
ec
to
fi
nt
en
siv
ev
er
su
sc
on
ve
nt
io
na
lg
ly
ce
m
ic
co
nt
ro
lo
n
di
ab
et
ic
co
m
pl
ic
at
io
ns
Re
tin
op
at
hy
N
eu
ro
pa
th
y
N
ep
hr
op
at
hy
C
ar
di
ov
as
cu
la
rd
ef
ec
ts
SD
IS
T1
D
96
5
+
+
+
N
A
D
CC
T
T1
D
14
41
6.
5
+
+
+
=
D
CC
T/
ED
IC
T1
D
13
75
8
N
A
N
A
+
+
D
CC
T/
ED
IC
T1
D
12
14
18
+
N
A
N
A
N
A
KP
CT
T2
D
11
0
6
+
+
+
N
A
ST
EN
O
2
T2
D
16
0
7.8
+
+
+
+
U
KP
D
S
T2
D
38
67
10
+
N
A
+∗
=
VA
D
T
T2
D
17
91
5.
6
=
=
=
=
A
D
VA
N
CE
T2
D
11
14
0
5
=
N
A
+
=
AC
CO
RD
T2
D
10
25
1
3.
5
N
A
N
A
N
A
−
+,
be
ne
fit
;=
,n
o
ch
an
ge
;−
,h
ar
m
;N
A
,n
ot
as
se
ss
ed
.
Journal of Diabetes Research 7
Polyol 
pathway
Sorbitol
Aldose
reductase
Sorbitol
dehydrogenaseFructose
Glycolysis
NADH and
FADH2
Glyceraldehyde
C IIC IIIC IV
Q
e-
C I
NAD+
NADHFADFADH2ROS
Rise in voltage gradient
(mitochondrial dysfunction)
Reactive oxidised 
proteins and lipids
Mt DNA
Mt DNA damage
P
PKC and ATM
Cyt c
Methylglyoxal
AGEs RAGE
Excess glucoseEndothelial cell
Inflammatory
proteins
p53
iNOS
NO
NO
Nucleus
Cytoplasm
ETC
Apoptosis
NF𝜅
B
𝛾H2AX
𝛾H2AX
H
2
O
2
and NO
3
−
O
2
−
e−
e−
e−e−
e−
e−e−e−
e−e−
Mitochondria
Figure 2: Mechanisms of hyperglycemia-induced endothelial dysfunction. Key processes responsible for hyperglycemia-induced endothelial
dysfunction include the polyol pathway, reactive oxygen species (ROS) formation, and advanced glycation endproducts (AGEs) formation.
The excess glucose in endothelial cells enters polyol pathway; the electron donors like reduced nicotinamide adenine dinucleotide (NADH)
and Flavin adenine dinucleotide (FADH2) accumulate in the mitochondria, thus affecting the electron transport chain; the excess electrons
increase ROS in mitochondria; ROS triggers accumulation of AGEs; ROS and AGEs create mitochondrial DNA damage and mitochondrial
dysfunction; protein kinase C (PKC) and AGEmediated activation of nuclear factor kappa B (NF𝜅B) activate the expression of inflammation
proteins, tumor suppressor p53, and inducible nitric oxide synthase (iNOS); increased nitric oxide (NO) by iNOS is highly reactive with
superoxide anions; the peroxynitrite thus generated acts as a strong oxidant and completes the vicious cycle of oxidative stress by increasing
ROS production; accumulation of AGEs also increases ROS production independent of glucose levels.
and excessive ROS production [57, 58]. AGEs induce nicoti-
namide adenine dinucleotide phosphate (NADP) reduction,
thus leading to generation of more reactive superoxides [59].
Since enzymatic removal of glycation from AGEs has not
been reported (except for HbA1c), it is accepted that AGE
formation is an irreversible process. Therefore, AGEs will
persist in diabetic tissues even with a tight glycemic control.
In addition, AGEs are reported to elevate ROS production,
independently of hyperglycemia [59]. Considering all this
information, AGEs are likely to be one of the components
of glycemic memory that leads to diabetic complications.
AGEs require hyperglycemia for their formation, but once
irreversibly formed their persistent presence can activate
oxidative stress and inflammatory mechanisms to drive the
development of vascular complications.
Accumulation of AGEs in skin collagen even after HbA1c
normalization in 211 diabetic patients from DCCT/EDIC
trials suggests that AGEs are reliable biomarkers of glycemic
memory that correlate with the risk of diabetic retinopathy
progression [60]. AGE levels have also been shown to
correlate with heart failure and cardiovascular events [61].
Therefore, AGEs serve as biomarkers for the cumulative
burden of tissues exposed to dyslipidemia, oxidative stress,
and inflammation, in addition to hyperglycemia [62]. We
believe that AGEs can be clinically useful for themanagement
of diabetic patients as prognostic biomarkers for the devel-
opment of complications, while scientifically AGEs represent
reliable markers for glycemic memory.
4. Epigenetics to Explain Glycemic Memory
4.1. Epigenetic Basic Mechanisms. Epigenetic processes are
described as changes in gene expression and phenotype
caused by alterations in the genome that do not involve
changes in DNA sequence [63]. Epigenetic mechanisms can
be widely classified based on their short- or long-term effect.
The short-term effect often involves a rapid response to
varying environmental factors and is nonheritable in nature.
The long-term effect on the other hand creates a persistent
change that is stored as “memory” and passed on to the
offspring, usually in response to excessive exposure to long
acting stimuli [64]. However, it has been reported that even
a transient change in the microenvironment can induce
persisting epigenetic effects [22].
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Epigenetic mechanisms are divided into three main
categories: posttranslational histonemodifications (PTHMs),
DNA methylation, and microRNA-mediated translational
control. PTHMs comprise a complex variety of biochemical
reactions such as acetylation, methylation, phosphorylation,
and ubiquitination. A combination of different PTHMs
collectively acts in unison to create a local chromatin mod-
ification pattern. Histone acetylation of lysine residues in
H3 and H4 subunits results in euchromatin conformation
(active state). This reversible acetylation reaction is catalyzed
by the enzyme histone acetyl transferase (HAT), while the
deacetylation is induced by the enzyme histone deacety-
lase (HDAC) [65]. Deacetylation converts euchromatin to
heterochromatin (inactive state) and consequently causes
transcriptional silencing. Histone methylation is another
important PTHM where the enzyme histone methyl trans-
ferase (HMT) adds methyl groups from S-adenosyl methio-
nine to the amine terminal of lysine or arginine [66–68].
Unlike histone acetylation, histone methylation activates or
silences transcription based on the position of lysine or
arginine residues and the number of methyl groups added.
For example, mono-, di-, and trimethylated H3K4 result in
euchromatin, while mono-, di-, and trimethylated H3K9,
H3K27, and H4K20 result in heterochromatin [69].
DNA methylation is characterized by the addition of
a methyl group to the cytosine residue in the CpG din-
ucleotide sequence by DNA methyl transferase enzymes
(DNMTs). The extent of DNA methylation at CpG islands
(genomic regions with high density of CpG dinucleotides)
located in promoter regions determines the transcription
status of the gene [70]. DNMT1 classically functions as a
maintenance DNMT as it conserves the methylation pattern
during replication, while DNMT3A and DNMT3B create de
novomethylation marks [71]. DNA methylation at promoter
regions is usually inversely associated with regulation of gene
expression. Therefore hypermethylation is associated with a
blockade of normal gene expression [70]. DNA demethy-
lation is another important phenomenon observed during
embryogenesis and certain disease conditions.The demethy-
lation process often results from absence of methylation
pattern maintenance by DNMT1 (passive demethylation) or
enzyme mediated excision of methylated cytosine (active
demethylation). A class of enzymes called demethylases
belonging to the family of MBD (methyl CpG-binding
domain) proteins mediates the active demethylation process
[72]. DNA methylation/demethylation is a dynamic process
occurring simultaneously that regulates cellular functions
and selectively triggers or represses gene expression.
It has been established that there exists a crosstalk
between PTHMs and DNA methylation and that they are
highly interdependent in determining gene expression status
[73]. For example, low DNA methylation combined with
H3K4 methylation and acetylation of H3K and H4K results
in euchromatin structure. Contrarily, high DNAmethylation
combined with H3K9 methylation and deacetylation of H3K
and H4K results in heterochromatin structure [74]. MicroR-
NAs (miRNAs) constitute a very different class of epigenetic
controls. These single stranded noncoding RNA molecules
interact with transcribedmRNA to inhibit translation, unlike
PTHMs and DNA methylation, which act on the genome
before transcription. miRNAs are transcribed independently
and are present in the intergenic regions, exons, or protein
coding introns. miRNAs bind to the 3󸀠 untranslated region
(3󸀠UTR) of targeted mRNA and inhibit translation by either
degradation of mRNA or destabilization by cleavage and
deadenylation [75].
4.2. Specific Epigenetic Changes Associated with
Glycemic Memory
4.2.1. Histone Modifications. The association of certain his-
tone modifications and glycemic memory was confirmed
when a cohort of patients from the DCCT/EDIC trial
follow-up were investigated. This study provided evidence of
increased acetylation of H3K9 at promoters of genes related
to interferon regulatory factors, inflammation, apoptosis,
NF𝜅B pathway, and ROS in monocytes of 30 patients from
the conventional diabetic control group. These epigenetic
changes were coupled to prolonged upregulation of STAT1,
TNF𝛼, and IL1A and correlated clinically with occurrence of
chronic diabetic complications [76].
A correlation between increased ROS and persistent
histone modifications was demonstrated using rat retinal
endothelial cells. Persistent reduced levels of H3K4me1
and H3K4me2 and increased recruitment of lysine spe-
cific demethylase, LSD1, were observed at the promoter of
superoxide dismutase 2 (SOD2) gene in rats maintained at
poor glycemic control (6 months of poor control) and the
memory group (3 months of poor control and 3 months of
good control). Consequent SOD2 decrease was associated
with the development of diabetic retinopathy over time
[77]. It has also been reported that in retinas from diabetic
rats there was a significant increase of H4K20m3 at the
promoter and enhancer of SOD2 which was in agreement
with an upregulation of methyltransferase, SUV420h2. Most
importantly, reversal of hyperglycemia failed to prevent these
changes, suggesting the existence of glycemic memory in
the diabetic retina driven by histone modifications [78].
Changes in the levels of histone modifying enzymes have
been demonstrated in the same experimental model. Retinal
endothelial cells from the poor control and memory group
showed a significant increase in HDAC levels and decrease in
HAT levels [79].These changes in histone acetylation induced
by hyperglycemia remained unchanged even after a 3-month
return to normoglycemic conditions, thus confirming the
existence of metabolic memory in retinal endothelial cells
[79].
In addition, there are several reports highlighting that
histone modifications represent an important mechanism
triggered by hyperglycemia that leads to endothelial dysfunc-
tion (Table 2). For example, the repressive mark H3K9me3
was significantly decreased at the promoters of inflammatory
genes in diabetic rat VSMCs. The resulting proinflammatory
and atherosclerotic phenotype persisted even after cultur-
ing the cells in normal glucose levels for several passages
[30]. Human microvascular endothelial cells exposed to
high glucose exhibited increased levels of H3K4me1 and
reduced levels of H3K9me2 and H3K9me3 at the promoter
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of NF𝜅B p65.This combination of histonemethylationmarks
induced upregulation of NF𝜅B p65 expression which trig-
gered the transcription of numerous inflammatory cytokines
[80]. Similarly, a study on human aortic endothelial cells
acutely exposed to high glucose reported that the histone
methyltransferase Set7 was mobilized to the p65 promoter,
resulting in a significant increase in H3K4 monomethylation
[22]. Methyltransferases Set7 and SUV39h1 and demethy-
lase LSD-1, recruited to the promoter of NF𝜅B, generate
respective histone methylation changes [80]. Interestingly,
the H3K4 methyltransferase Set7 has been proposed as a
critical mediator of the phenomenon of glycemic mem-
ory [81]. Set7 accumulated in the nucleus of endothelial
cells in response to hyperglycemia and drove activation of
numerous proinflammatory genes that persisted even when
switched back to normoglycemic conditions. Set7/9 have also
been proposed as therapeutic targets to modulate epigenetic
marks in diabetes. Knockdown of Set7/9 in monocytes was
reported to significantly repress NF𝜅B and its downstream
inflammatory genes like TNF𝛼 and interleukins. In addition,
monocyte adhesion to vascular endothelial and smooth
muscle cells was also prevented, thus protecting the endothe-
lium from diabetes induced inflammation [82]. However,
knockdown of Set7/9 did not reduce the H3K4 methylation
at the promoters of the downstream inflammatory genes.
This suggests that loss of Set7/9 is compensated by other
histone methyltransferases like Set1, SMYD3, and MLLs
[69].
The histone acetyltransferase cofactor, p300, has been
shown to regulate the hyperglycemia-induced gene expres-
sion changes in HUVECs. Cells incubated in 25mM glucose
for 24 hours were reported to exhibit increased expression
of p300 which accumulated at the promoters of endothelin-
1 (ET-1), VEGF, and fibronectin along with inducing phos-
phorylation of H2AX and histone acetylation. Inhibition
of p300 via siRNA led to decreased mRNA levels of ET-1,
fibronectin, and VEGF due to reduced histone acetylation
at their promoters [83]. HATs and HDACs often act in
complexes with corepressors or transcription factors and
exhibit high specificity for acetylation sites, thusmaking them
complex to use as drug targets [84]. However, some Histone
deacetylase inhibitors (HDIs) used in cancer have been
demonstrated to inhibit all the HDACs [85]. Sirtuin 1 (SIRT1)
is a class 3 HDAC that has been linked with angiogenesis
[86]. This deacetylase enzyme is observed to be significantly
downregulated in endothelial cells exposed to high glucose
[87]. In addition, SIRT1 is also significantly downregulated
in senescent endothelial progenitor cells (EPCs); and its
upregulation using the SIRT1 activator resveratrol proved
helpful in rescuing the EPC senescent phenotype [88].
The expression of eNOS, an essential enzyme for endothe-
lial cell function, has been reported to be controlled by a
specific histone code described as H3K9ac and H3K12ac
along with H3K4me2 and H3K4me3. This histone code
acts like a switch for eNOS expression and is reversed in
nonendothelial cells [89].
Treatment of endothelial cells with a H3K4 methylation
inhibitor methylthioadenosine resulted in decreased eNOS
expression, while treating nonexpressing cells with histone
deacetylase inhibitor, trichostatin-A, increased eNOS expres-
sion [89]. The H3K27me3 mark at eNOS promoter was
described as a repressor for eNOS expression in early EPCs.
A combination of trichostatin-A and DNMT inhibitor, 3-
deazaneplanocin, was effective in removing this repressive
histone code [90]. Since impairments in eNOS-related path-
ways are associatedwith endothelial dysfunction, it is possible
that modulation of epigenetic marks at the eNOS promoter
could become a potential target for treating endothelial
dysfunction.
4.2.2. DNA Methylation. DNA methylation has not been
investigated in endothelial cells under diabetic conditions as
extensively as histone modifications. However, there is some
interesting evidence to suggest a role for DNA methylation
in directing progression of diabetic vascular complications
(Table 2). For example, a genome-wide DNA methylation
analysis from whole blood of type 1 diabetic patients with
or without renal disorders identified hypermethylation of
UNC13B promoter in the diabetic nephropathy group. This
is relevant because UNC13b is critical for regulation of
glomerular apoptosis and has been recently implicated in
the pathology of diabetic nephropathy [91]. A recent study
also reported a role for DNA methylation in the develop-
ment of diabetic foot ulcers. Global hypomethylation was
observed in diabetic foot ulcer fibroblasts when compared
to nondiabetic counterparts. Functional enrichment analysis
highlighted differential methylation of gene clusters involved
in angiogenesis, myofibril function, and extracellular matrix.
All of these nodes are directly related to the wound healing
process and comprise genes such as COL4A1, PLAU1, and
FGF1. These DNA methylation changes persisted even after
culturing the diabetic patient fibroblasts for several passages
under normal glucose levels [92].
DNA methylation has been recently associated with
glycemic memory and progression of diabetic retinopathy in
a diabetic ratmodel. Using diabetic retinal tissue and cultured
retinal endothelial cells, it was found that POLG1 promoter
was hypermethylated in the diabetic group, in both retinal
tissue and cultured cells. This hypermethylation continued
to persist in both in vitro and in vivo experimental models
of glycemic memory [93]. Furthermore, DNMT activity was
significantly increased in the diabetic and memory groups.
These data indicated that after a 3-month period of hyper-
glycemic insult there was increased DNA methylation of
POLG1 promoter coupled with increasedDNMT activity that
persisted for further 3 months even when normal glycemic
control was reinstituted. Although this evidence shows that
diabetes clearly has an effect on DNA methylation, it is
important to acknowledge that there are many other factors
that can modulate DNA methylation profiles. For example,
disturbed blood flow has been demonstrated to significantly
change the DNA methylation patterns of murine arterial
endothelial cells by an increased expression of DNMT1 and
promoter hypermethylation of 11 proatherosclerotic genes
[94].
4.2.3. miRNAs. miRNAs are an important class of gene
expression regulators and have been widely implicated in
Journal of Diabetes Research 11
diabetic pathology. miRNA profiling of 80 type 2 diabetic
patients compared with age and gender matched controls
showed overexpression of miR-28-3p and underexpression
of 12 miRNAs (miR-223, miR-320, miR-486, miR-150, miR-
24, miR-21, miR-29b, miR-20b, miR-15a, miR-126, miR-191,
and miR-197). These miRNA markers enabled prediction
of diabetes prognosis for 70% patients [95]. A recent com-
prehensive review has described various groups of miRNAs
that play a deterministic role in the development of diabetic
complications [96].
Despite the extensive number of studies profiling miR-
NAs in diabetic tissue, few focus on glycemic memory. This
might be due to the intrinsic short-term effects and fast
kinetic mechanisms of miRNAs, while glycemic memory
requires long-term irreversible mechanisms.
The use of miRNA inhibitors such as antagomirs is being
investigated as a novel approach to treat several metabolic
disorders. The specificity of antagomirs makes them efficient
candidates to be used for targeted deletion of miRNAs
without disturbing the balance of other miRNAs with similar
structure, even at the single nucleotide polymorphism level
[97]. However, miRNA knockdown requires multiple doses
at regular intervals because antagomirs erase a specific group
of miRNAs for up to only 20 days [98]. Nevertheless, future
research based on using miRNA inhibitors might assist
in the development of new therapies for diabetic vascular
complications.
5. Endothelial Progenitors and
Glycemic Memory
5.1. Endothelial Progenitor Cells. Endothelial progenitor cells
(EPCs) are a subpopulation of low-frequency cells found in
circulation. They are said to originate from bone marrow
and navigate through the circulation following chemokine
signalling to reach sites that require neovascularization and
vascular repair [99]. Over the last decade, EPCs have been
thoroughly examined due to their intrinsic potential to
promote and contribute to new blood vessel formation. They
may also be used as potential biomarkers to identify onset and
progression of vascular disease [100] and to study vascular
biology and pathogenesis in a Petri dish [101]. EPCs were first
identified in 1997 in a seminal study by Asahara et al. who
proposed that angioblasts and hematopoietic stem cells arise
from a common precursor as they possess similar surface
antigen profiles that include CD34, Tie2, and Flk-1 [102].
EPCs were isolated by sorting CD34+ cells and plating them
on fibronectin-coated Petri dishes. The cells that emerged
were found to express endothelial markers CD31, VEGFR2,
Tie2, and E-selectin and when tested in an ischemic limb
model they were found to incorporate into sites of active
angiogenesis [102].
5.1.1. Controversy around Different Subsets of EPC. Since
Asahara et al.’s discovery [102], over a decade ago, there has
been a considerable amount of controversy surrounding the
EPC field due to the results of preclinical studies being largely
inconsistent when compared to clinical trials. This is most
likely due to the fact that heterogeneous and different popula-
tions of cells classed as EPCs have been used in experimental
models and trials.The problem stems from the fact that there
is no definitive cell surface marker used to identify EPCs
that clearly distinguishes them from hematopoietic cells and
mature vessel wall endothelial cells [103].
Two main approaches have been used to isolate EPCs.
The first is (A) cell surface selection using progenitor and
endothelial markers. The main markers used for EPC selec-
tion are progenitormarkers such as CD34 andCD133 in com-
bination with an endothelial marker such as VEGFR2. The
second is (B) differential cell culture methodologies. It is now
well accepted that using such in vitro isolation methods leads
to the identification of at least two main and distinct subsets
of cell that exhibit very different morphological and angio-
genic properties [104, 105]. The first cell type arises within
one week of culture as spindle-shaped cells. They uptake
acetylated LDL, bind lectin, and express endothelial markers
CD31 and VEGFR2. These are commonly known as early
EPCs (eEPCs) due to their early appearance in culture. eEPCs
are often termed proangiogenic monocytes/hematopoietic
cells, myeloid angiogenic cells (MACs) [104, 106], and cir-
culating angiogenic cells (CACs). The second subset of cells
arises much later in culture, at around 2–4 weeks, and
exhibits cobblestonemorphology.They display unambiguous
commitment to endothelial lineage and are often referred
to as endothelial colony forming cells (ECFCs) [107, 108] or
outgrowth endothelial cells (OECs) [109]. In spite of falling
under the term EPCs, the two cell subtypes, eEPCs and
ECFCs, have been shown to possess very different molecular
profiles and functional characteristics [105]. Evidence in the
literature suggests that only ECFCs represent the bona fide
EPC owing to their unequivocal expression of a wide range
of endothelial markers (thrombomodulin, CD146, CD34,
VE-cadherin, CD31, and vWF), negativity to hematopoietic
markers (CD45 andCD14), endothelial functionality, and sig-
nificant proliferative potential [109, 110]. ECFC-like cells can
also be generated from induced pluripotent stem cells (iPSCs)
and human embryonic stem cells (hESCs). Pluripotent stem
cell-derivedECFC-like cells displayed similar phenotypic and
functional characteristics to umbilical cord blood-derived
ECFCs. iPSC-derived ECFCs maintained an endothelial
phenotype, displayed high clonal proliferative potential, and
importantly formed vascular structures in multiple animal
models of ischemia [111].
5.1.2. Sources for Isolation, Mobilization, and Niches. EPCs
can be isolated from adult peripheral blood, bone mar-
row, and umbilical cord blood. While umbilical cord blood
remains the classical source for isolation of ECFCs, other
tissues such as placenta, lungs, and white adipose tissue
have also been reported as alternative sources [112–114]. The
mobilization of EPCs from bone marrow to sites of vascular
trauma is mediated by metalloproteinases that release the
precursors from the stroma followed by upregulation of
adhesion molecules and factors like vascular endothelial
growth factor (VEGF) and granulocyte colony stimulating
factor (G-CSF) that assist trafficking of the cells through
circulation and finally lead to subsequent homing [115]. EPCs
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are also believed to be present in additional niches like the
vascular wall [116]. A specific “vasculogenic zone” has been
reported to be present in all adult blood vessels that might
act as a source of EPCs [117, 118].
5.1.3. Therapeutic Potential. EPCs may be used for therapeu-
tic purposes to aid regeneration of ischemic tissues due to
their ability to migrate to remote areas and promote new
blood vessel formation in areas that have suffered vascular
insufficiency [119]. There are various advantages in using
these cells as they can be isolated from the patient and
expanded in vitro to be delivered locally at the site of injury
as autologous cells that avoid immunogenic responses. Under
hypoxic conditions, EPCs have the ability to mobilize from
their vascular niche into the circulation where they can
target and home to specific ischemic tissues. HIF-1𝛼 and
SDF/CXCR4 signalling are known to play key roles in EPC
migration to ischemic tissue, as blockade of these signalling
pathways results in a dramatic reduction in EPC homing and
consequent impaired neovascularization [120].
5.2. EPCs and Diabetes. Hyperglycemia significantly alters
endothelial cell biology and leads to a delayed heal-
ing response to injuries and vasodegenerative micro- and
macrovascular complications. EPC number and function
have been shown to be significantly reduced in diabetic
patients. Levels of circulating EPCs are reduced by up to
50% in diabetic patients when compared to nondiabetic
controls [121]. CD34 expressing progenitors were also found
to be reduced in type 2 diabetic patients when compared
to healthy controls. Furthermore, these putative EPCs were
found to negatively correlate with disease severity [122].
In addition, it has been reported that EPCs derived from
diabetic individuals exhibit a diminished vasoreparative
potential [123], display an impaired migratory activity, and
undergo premature senescence [124, 125]. ECFCs isolated
from umbilical cord blood of diabetic patients exhibited
reduced colony forming ability and decreased tube forming
capacity in matrigel, when compared to ECFCs derived from
nondiabetics [125]. It has also been shown that diabetic rats
have decreased levels of circulating EPCs as a result of bone
marrow neuropathy, and this phenomenon is said to precede
the development of diabetic retinopathy [126].
5.3. EPC Differentiation and Epigenetics. Heterochromatin
protein-1 alpha (HP-1𝛼), an epigenetic regulator implicated in
gene silencing, has been reported to play an important role
in promoting EPC differentiation in vitro and in vivo [127].
Repressive H3K27me3 and DNA methylation marks were
recently reported in eNOS promoters of early EPCs, which
were reversed in hypoxic conditions to increase eNOS expres-
sion, consequently increasing endothelial recruitment and
differentiation [90]. HDAC1, a histone deacetylase enzyme, is
also known to play a key role in inhibiting endothelial differ-
entiation and proliferation [128]. The use of epigenetic drugs
to reverse these epigenetic marks is being studied recently as
a strategy to enhance revascularization [129]. Trichostatin-A
is a histone deacetylase inhibitor which has been used to treat
ECFCs before transplantation into ischemic tissues in order
to increase revascularization efficiency [130].
5.4. Why Might Glycemic Memory Be Relevant for
EPC Biology?
5.4.1. Progenitor Concept. Although EPCs are considered to
be more resistant to oxidative stress than mature endothelial
cells, these cells have been shown to be vulnerable in a
diabetic environment [131]. Experimental evidence demon-
strates that prolonged exposure of EPCs to oxidative stress
compromises their reparative potential [132]. EPCs exposed
to hyperglycemia for prolonged periods displayed reduced
migration and adhesive properties in vitro and impaired
recruitment to neoendothelium in vivo. This phenomenon
of EPC dysfunction can be attributed to lowered levels of
cathepsin-L activity and upregulation of thrombospondin-
1, which were responsible for impaired EPC migration and
adhesion, respectively [133, 134].
Nevertheless, when compared to their mature coun-
terparts, progenitor cells, that is, ECFCs/OECs, have been
shown to undergo a higher number of population doublings
and possess a longer in vitro lifespan [135]. Furthermore,
umbilical cord blood-derived ECFCs have an enhanced
proliferative potential when compared to those obtained
from peripheral blood [109]. Mature endothelial cells prolif-
erative capacity is known to be limited; indeed, under high
glucose conditions mature endothelial cells readily undergo
premature senescence [136]. These data led us to hypothesize
that, following exposure to the diabetic milieu, the endoge-
nous, resident pool of reparative endothelial progenitors may
become damaged. Indeed, these EPCs have an important
vascular homeostatic role and this cellular reserve could serve
as potential “carriers” of the endothelial glycemic memory in
diabetic patients.
5.4.2. Therapeutic Potential and Modulation of EPCs. EPCs
have considerable potential for autologous cell therapy. This
involves cell isolation from patients’ own blood which are
then expanded in culture and given directly back to the
same patient. In the context of diabetes, patient-derived EPCs
may carry a “memory” of their former hyperglycemic envi-
ronment which might significantly affect their function. For
ECFCs, in particular, this detrimental effect of diabetes has
been previously demonstrated. When ECFCs were exposed
to high glucose conditions in vitro or a diabetic environment
in vivo, they exhibited diminished function such as reduced
colony formation, decreased self-renewal capacity, and tube
formation [125].This was a direct result from exposure to the
diabetic milieu. Therefore, there is a need to modulate the
function of such “diseased diabetic EPCs/ECFCs” in order to
restore normal angiogenic function before their final use as a
cytotherapy.
Some reports have started to emerge suggesting various
strategies to reverse EPC dysfunction caused by diabetes.
Rosiglitazone treatment [137], enhancement of angiogenic
stimulus using G-CSF [138], promoting cell deformability,
and usage of nitric oxide donor to reverse SDF-1 medi-
ated migration defects [139] are some of the approaches
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employed to overcome the consequences of EPCdysfunction.
However, it must also be taken into consideration that
these corrective measures might not be fully successful
due to the unfavourable milieu in diabetic tissues [140].
Advanced glycation endproducts cause damage to capillary
basement membrane that hinders homing of EPCs. This
shortcoming can be overcome by studying EPC interactions
with substrates and learning how to modulate these [141].
Modification of the diabetic microenvironment prior to cell
delivery is an important area that requires further research.
6. Concluding Remarks
Epidemiological and experimental evidence accumulated
over the last two decades has proven the existence of a
glycemic memory phenomenon triggered by uncontrolled
hyperglycemia in the early stages of disease. The consensus
view is that an effective way to diminish diabetic vascular
complications is early diagnosis and initiation of appropriate
glycemic control measures. This will prevent the imprinting
of glycemic memory in endothelial (and other) cells and
consequently result in a slower progression of vascular
complications.
While oxidative stress and AGE accumulation seem to be
the key biochemical drivers of glycemic memory, epigenetic
changes such as histone modifications and DNAmethylation
appear to modulate glycemic memory at the molecular level.
Furthermore, it seems likely that endogenous endothelial
progenitors represent a significant cellular component where
all these biochemical and molecular processes take place.
Considering their extended lifespan and vascular homeo-
static function, it is likely that the glycemic memory affects
EPCs and that this contributes to the impaired vasoreparative
capacities of diabetic tissues.
There is a pressing need for new therapeutic targets to
address the glycemic memory phenomenon. Among many
candidates, drugs that modulate epigenetic mechanisms have
the potential to “erase” the glycemic memory and conse-
quently delay progression of microvascular complications.
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